Introduction
The COVID-19 pandemic has had a profound impact on the general population and the burden of preexisting comorbidities heavily affected the outcome of the infection. Hyponatremia has been frequently described. Conversely, hypernatremia has rarely been described in COVID-19.
Methods
The studied cohort encompasses all COVID-19 patients consecutively admitted to the Messina hospital, Italy, during the first wave of the epidemic. Since healthcare structures were not overwhelmed in that period, indications for hospitalization were homogeneous throughout the study period. Serum sodium levels (Na), kidney function (eGFR), demographic and clinical characteristics were recorded at admission. Correlation between mortality, Na and eGFR was evaluated by survival curves and univariate and multivariate regression models.
Results
Baseline biochemical and clinical data at the time of admission were available for 115 COVID-19 confirmed patients. Median age at admission was 73 years (48% men), with a median Charlson Comorbidity Index of 4. 23.5% of patients presented with Na ≥ 146 mmol/l while 7.8% had Na < 135 mmol/l. Hypernatremic patients were older with higher comorbidity. Age, hypernatremia and reduced eGFR were associated with increased mortality in both univariate and multivariate regression models (p < 0.001). The combination of hypernatremia and reduced renal function at admission bore an odds ratio of 47.67 [95%CI 10.08-225.43] of dying compared to patients with eGFR≥60 ml/min and a Na < 145 mmol/l.
Conclusions
Our study suggests that the association between hypernatremia and reduced eGFR at referral is a highly relevant prognostic marker for death during hospitalisation. The role of this association should be further tested in larger, multicentre cohorts.